



National Institutes of Health
National Institute of Dental
and Craniofacial Research
Bethesda, Maryland 20892

July 13, 2018

James Love
Knowledge Ecology International
1621 Connecticut Avenue, Suite 500
Washington, DC 20009
James.Love@keionline.org

IN RE: 83 Federal Register 29127 (June 22, 2018), "Prospective grant of an exclusive patent license: Methods of modulating erythropoiesis with arginine vasopressin receptor 1B molecules"

Dear James Love:

Thank you for providing us with your comments regarding the notice of the proposed license the National Institute of Dental and Craniofacial Research intended to grant to ERYTHRYx Therapeutics. Prior to posting a notice for a proposed grant of an exclusive license, the NIH determines that the criteria set forth in 37 CFR 404.7(a)(1)(ii-iii) have been satisfied and that the company is qualified both technically and financially to be granted an exclusive license to the Government's intellectual property in the fields of use as specified. The notice period provides an opportunity for public comment and possible objection to the proposed license. We consider all comments prior to negotiating the proposed license and have considered your comments.

With respect to your request for various reports, it is not consistent with our mission to create reports requested by the public. If your organization is requesting documents, such requests should be filed under the Freedom of Information Act. The webpage for the NIH FOIA Office provides more information on filing requests: www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office/submitting-foia-requests

Sincerely,

David W. Bradley, Ph.D.
Director
Office of Technology Transfer and Innovation Access
National Institute of Dental and Craniofacial Research
National Institutes of Health